Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under the Renerve, Unibrol, Combiart, Duotab, and Vitafer brands; and anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for institutional business. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. The company was incorporated in 1990 and is based in Bengaluru, India.
| Current Price | ₹1,075.00 |
|---|---|
| Market Cap | ₹9,909 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Products |
| P/E Ratio | 17.8 |
| Return on Equity | 20.03% |
| 52-Week Range | ₹768.65 – ₹1,231.00 |
| Beta (1Y) | 0.43 |
| Dividend Yield | 0.47% |
1. Pharmaceutical Business (Excl. Bio-Pharmaceutical Business)-100%
Strides Pharma Science Limited (Star) is trading at ₹1,075.00, with a market capitalisation of ₹9,909 Cr.
Strides Pharma Science Limited (Star) operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Products).
Strides Pharma Science Limited (Star) has a P/E of 17.8 and a return on equity of 20.03%.